[1] LUKACSI S,MACSIK V B,NAGY B Z,et al. Utilization of complement receptors in immune cell-microbe interaction[J]. FEBS Letters,2020,594(16):2695-2713. [2] HANNAN J P. The structure-function relationships of complement receptor type 2(CR2; CD21)[J]. Current Protein & Peptide Science,2016,17: 463-487. [3] TEW J G,WU J,QIN D,et al. Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells[J]. Immunological Reviews,1997,156:39-52. [4] NIELSEN C H,FISCHER E M,LESLIE R G. The role of complement in the acquired immune response[J]. Immunology,2000,100(1):4-12. [5] YOUNG K A,CHEN X S,HOLERS V M,et al. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2(CR2/CD21)[J]. Journal of Biological Chemistry,2007,282(50):36614-36625. [6] PESTKA S,LANGER J A,ZOON K C,et al. Interferons and their actions[J]. Annual Review of Biochemistry,1987,56: 727-777. [7] BILLIAU A,MATTHYS P. Interferon-gamma: A historical perspective[J].Cytokine & Growth Factor Reviews,2009,20:97-113. [8] CAPOBIANCHI M R,ULERI E,CAGLIOTI C,et al. Type Ⅰ IFN family members: Similarity,differences and interaction[J]. Cytokine & Growth Factor Reviews,2015,26(2):103-111. [9] BROGGI A,GRANUCCI F,ZANONI I. Type Ⅲ interferons: Balancing tissue tolerance and resistance to pathogen invasion[J].Journal of Experimental Medicine,2020,217(1): e20190295. [10] LIU W,ZHANG S,WANG J. IFN-γ,should not be ignored in SLE[J]. Frontiers in Immunology,2022,13:954706. [11] POGUE S L,PRESTON B T,STALDER J,et al. The receptor for type Ⅰ IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells[J].Journal of Interferon & Cytokine Research,2004,24: 131-139 [12] ASOKAN R,HUA J,YOUNG K A,et al. Characterization of human complement receptor type 2(CR2/CD21) as a receptor for IFN-alpha: A potential role in systemic lupus erythematosus[J].The Journal of Immunology, 2006,177(1):383-394. [13] SUGANO N,CHEN W,ROBERTS M L,et al. Cooper. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-κB induction[J]. Journal of Experimental Medicine,1997,186: 731-737. [14] ADDARIO M,LIBERMANN T A,XU J,et al. Epstein-Barr virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21,involving activation of NF-κB and different signaling pathways[J].Journal of Molecular Biology,2001,308: 501-514. [15] AUBRY J P,POCHON S,GRABER P,et al. CD21 is a ligand for CD23 and regulates IgE production[J]. Nature,1992,358: 505-507. [16] DELCAYRE A X,SALAS F,MATHUR S,et al. Epstein-Barr virus/complement C3d receptor is an interferon alpha receptor[J]. The EMBO Journal,1991,10: 919-926. [17] DARNELL J E,KERR I M,STARK G R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J].Science,1994,264:1415-1421. [18] PINI L,RASTELLI G. Molecular docking: Shifting paradigms in drug discovery[J]. International Journal of Molecular Sciences,2019,20(18):4331. [19] FENG Y,YAN Y,HE J,et al. Docking and scoring for nucleic acid-ligand interactions: Principles and current status[J]. Drug Discovery Today,2022,27(3):838-847. [20] FENG Y,ZHANG K,WU Q,et al. NLDock: A fast nucleic acid-ligand docking algorithm for modeling RNA/DNA-ligand complexes[J].Journal of Chemical Information and Modeling,2021,61(9):4771-4782. [21] IIDA K,NADLER L,NUSSENZWEIG V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody[J].Journal of Experimental Medicine,1983,158:1021-1033. [22] FINGEROTH J D,WEIS J J,TEDDER T F,et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2[J]. Proceedings of the National Academy of Sciences of the United States of America,1984,81:4510-4514. [23] AUBRY J P,POCHON S,GAUCHAT J F,et al. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21[J]. Journal of Immunology,1994,152: 5806-5813. [24] JIN H,KONG Z,JIANG B,et al. Identification and characterization of chCR2,a protein that binds chicken complement component 3d[J].Journal of Immunology,2023,210(9):1408-1418. [25] RAUW F,GARDIN Y,PALYA V,et al. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine[J]. Veterinary Immunology and Immunopathology,2010,134(3-4):249-258. [26] FERREIRA L G,DOS SANTOS R N,OLIYA G,et al. Molecular docking and structure-based drug design strategies[J]. Molecules,2015,20(7):13384-13421. [27] FERREIA L G,DOS SANTOS R N,OLIVA G,et al. Molecular docking and structure-based drug design strategies[J].Molecules,2015,20(7):13384-13421. [28] MARRAKCHI H,LANEELLE G, QUEMARD A. InhA,a target of the antituberculous drug isoniazid,is involved in a mycobacterial fatty acid elongation system,FAS-Ⅱ[J].Microbiology,2000,146:289-296. [29] WAHID A A,DUNPHY R W,MACPHERSON A,et al. Insights into the structure-function relationships of dimeric C3d fragments[J].Frontiers in Immunology,2021,12:714055. [30] JIN H,TU M,MENG Z,et al. Identification and structural analysis of dimeric chicken complement component 3d and its binding with chicken complement receptor 2[J].Developmental & Comparative Immunology,2024,152:105109. [31] TOAPANTA F R,ROSS T M. Complement-mediated activation of the adaptive immune responses: Role of C3d in linking the innate and adaptive immunity[J].Immunologic Research,2006,36(1-3):197-210. [32] LI K,OKEMEFUNA A I,GOR J,et al.Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2[J]. Journal of Molecular Biology,2008,384(1):137-150. [33] CARTER R H,FEARON D T. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM[J].The Journal Immunology,1989,143(6):1755-1760. [34] BOWER J F,YANG X,SODROSKI J,et al. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized Human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d[J].Journal of Virology,2004,78(9):4710-4719. [35] GREEN T D,NEWTON B R,ROTA P A,et al. C3d enhancement of neutralizing antibodies to measles hemagglutinin[J].Vaccine,2001,20(1-2):242-248. [36] ZHANG Z,LI Y,XU S,et al. Fusion to chicken C3d enhances the immunogenicity of the M2 protein of Avian influenza virus[J].Journal of Virology,2010,7:89. [37] 都兴洋. 表达鸡IFN-γ基因重组鸡痘病毒与鸡传染性法氏囊疫苗联合接种对鸡免疫应答的影响[D].呼和浩特:内蒙古农业大学,2006.DU X Y. Effect of rFPV-IFN-γ on active immunization induced by infectious bursal disease live vaxxine in chickens[D].Hohhot:Inner Mongolia Agricultural University,2006.(in Chinese) |